A Phase 2 interventional study of lenalidomide in Mantle Cell Lymphoma, sponsored by Celgene. Completed at 70 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-13.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell — 5 open to participants now, 8 under way, none of them phase 3. Lenalidomide · Lymphoma, Mantle-Cell.
Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, this one is the 5th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2008, is one of 18 in phase 2, and was the 6th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →5 of the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Peking University Third Hospital · Sites in China
Ages 18–80
Academic and Community Cancer Research United · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–80
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 30 · Phase 3 4
First in 2002; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 39 across the 43 interventional studies. Of the 31 that completed or were terminated, 16 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
13 studies in Lymphoma, Mantle-Cell by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 13 studies in Lymphoma, Mantle-Cell by Bristol-Myers Squibb, this one is the only one that started in 2008, is one of 3 in phase 2, and was the 3rd registered.
Bristol-Myers Squibb’s Lymphoma, Mantle-Cell studies by the year they started, since 2007.
4 of the studies testing lenalidomide in Lymphoma, Mantle-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06504199Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | 2026-12-31 |
| NCT05861050City of Hope Medical CenterGlofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | 2027-02-01 |
| NCT03523975City of Hope Medical CenterVenetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | 2027-06-24 |
| NCT07261163Institute of Hematology & Blood Diseases Hospital, ChinaObinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, from their registry updates:
Among Bristol-Myers Squibb’s 13 in Lymphoma, Mantle-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.
Follow up phase will continue until either 100% of the patients have died, are lost to follow up or have withdrawn consent or a maximum of 4 years from the last patient enrolled, whichever comes first. All other efficacy and safety endpoints will be updated at this time. In the unlikely event that the study will be closed and patients are still responding to treatment at this time, Celgene will discuss with the treating physicians options to provide further treatment to the patient after study closure in line with local regulation.
Follow up for second primary malignancies and OS will continue until 100% of the patients have died, are lost to follow up, have withdrawn consent, or a maximum of 5 years from the last patient enrolled, whichever comes first.
10 October 2017: In regard to the last subject last visit date/study completion date, the prolongation of timelines is due to the bridging of a treatment gap for a patient responding to study medication until non-study medication is available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following laboratory abnormalities
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single agent Lenalidomide Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but \< 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal.
Drug: lenalidomide
25mg oral capsules continuous days 1-21 each of a 28 day cycle
Also known as: Revlimid
Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses.
Time frame: From Day 1 of study treatment to progession or early treatment discontinuation; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days.
Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee
Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment.
Time frame: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days.
Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee
The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow.
Time frame: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days
Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee
Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment.
Time frame: From Day 1 of study drug to progression or early discontinuation; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee
Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment.
Time frame: From Day 1 of study drug to first documented date of disease progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee
Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir
Time frame: From Day 1 of study drug to first documented time of progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee
Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data.
Time frame: From Day 1 of study drug to first documented time of treatment failure; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Time to Response (TTR)
Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants.
Time frame: From Day 1 of study drug to time of first documented PR or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Time to Complete Response (CR+CRu) According to the Independent Review Committee
Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu.
Time frame: From Day 1 of study drug to first documented CR/CRu or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Overall Survival (OS)
Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive.
Time frame: From Day 1 of study drug to first documented date of progressive disease or death; up to the final data cut-off date of 30 March 2017; median duration of follow-up for surviving participants was 62.94 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.
Time frame: From the first dose of lenalidomide through 28 days after the last dose during the follow-up phase; median (minimum, maximum) duration of treatment was 94.0 (1.0, 1950 days)
Participants were enrolled and treated at 42 centers in 12 countries: US/ Puerto Rico, France, Israel, Belgium, Spain, Turkey, Austria, Hungary, Italy, Colombia, Germany, and Singapore.
| Milestone | Lenalidomide |
|---|---|
| Started | 134 |
| Completed | 1 |
| Not completed | 133 |
| Withdrew: Disease progression | 95 |
| Withdrew: Adverse event | 24 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Death | 4 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Other | 4 |
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses.
| percentage of participants | Lenalidomide |
|---|---|
| Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC) | 29.9 (22.26 to 38.36) |
Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment.
| months | Lenalidomide |
|---|---|
| Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee | 16.64 (10.4219 to 29.8191) |
The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow.
| percentage of participants | Lenalidomide |
|---|---|
| Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee | 9.0 (4.71 to 15.12) |
Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment.
| months | Lenalidomide |
|---|---|
| Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee | 24.43 (5.063 to NA) |
Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment.
| months | Lenalidomide |
|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee | 4.01 (3.6822 to 7.2329) |
Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir
| months | Lenalidomide |
|---|---|
| Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee | 5.46 (3.7479 to 9.4685) |
Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data.
| months | Lenalidomide |
|---|---|
| Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee | 3.75 (2.3342 to 4.6356) |
Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants.
| months | Lenalidomide |
|---|---|
| Time to Response (TTR) | 3.5 (1.7 to 15.9) |
Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu.
| months | Lenalidomide |
|---|---|
| Time to Complete Response (CR+CRu) According to the Independent Review Committee | 3.9 (1.9 to 13.0) |
Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive.
| months | Lenalidomide |
|---|---|
| Overall Survival (OS) | 19.50 (13.6767 to 25.5781) |
Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.
| participants | Lenalidomide |
|---|---|
| Any TEAE | 132 |
| Any TEAE Related to Investigational Product (IP) | 118 |
| Any TEAE Grade 3-5 AE | 106 |
| Any TEAE Grade 3 AE | 101 |
| Any TEAE Grade 4 AE | 57 |
| Any TEAE Grade 5 AE | 18 |
| Any Grade 3-5 AE Related to IP | 90 |
| Any Grade 3 AE Related to IP | 88 |
| Any Grade 4 AE Related to IP | 41 |
| Any Grade 5 AE Related to IP | 2 |
| Any TEAE Serious Adverse Event (SAE) | 70 |
| Any SAE Related to IP | 30 |
| Any TEAE Leading to Stopping of IP | 28 |
| Any Treatment Related AE Leading to Stopping IP | 16 |
| Any AE Leading to Dose Reduction | 55 |
| Any AE Leading to IP Interruption | 81 |
| Any Treatment Related AE Leading to Dose Reduction | 52 |
| Treatment Related AE Leading to IP Interruption | 66 |
Collected over From the first dose of 1enalidomide through 28 days after the last dose of lenalidomide; (maximum duration of study drug was 1940 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | 106/134 (79.1%) | 70/134 (52.2%) | 125/134 (93.3%) |
| Event | Lenalidomide |
|---|---|
| PNEUMONIAInfections and infestations | 8/134 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 7/134 |
| HYPOTENSIONVascular disorders | 7/134 |
| PYREXIAGeneral disorders | 6/134 |
| MANTLE CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/134 |
| SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/134 |
| ABDOMINAL PAINGastrointestinal disorders | 4/134 |
| PNEUMONIA BACTERIALInfections and infestations | 4/134 |
| DEHYDRATIONMetabolism and nutrition disorders | 4/134 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 4/134 |
| Event | Lenalidomide |
|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 68/134 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 51/134 |
| FATIGUEGeneral disorders | 47/134 |
| DIARRHOEAGastrointestinal disorders | 45/134 |
| ANAEMIABlood and lymphatic system disorders | 42/134 |
| NAUSEAGastrointestinal disorders | 41/134 |
| COUGHRespiratory, thoracic and mediastinal disorders | 41/134 |
| PYREXIAGeneral disorders | 30/134 |
| RASHSkin and subcutaneous tissue disorders | 30/134 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 24/134 |
The baseline characteristics are from the participants assesed within the intent to treat population (ITT), which included all enrolled participants who received at least one dose of study drug.
| Age, Continuous(Years) | Lenalidomide |
|---|---|
| Mean | 67.2 ± 8.38 |
| Age, Customized(Participants) | Lenalidomide |
|---|---|
| <65 | 49 |
| ≥ 65 | 85 |
| Sex: Female, Male(Participants) | Lenalidomide |
|---|---|
| Female | 26 |
| Male | 108 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide |
|---|---|
| White or Caucasian | 128 |
| Asian | 3 |
| Black or African American | 1 |
| Other | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Lenalidomide |
|---|---|
| 0 = (Fully Active) | 43 |
| 1 = (Restrictive but ambulatory) | 73 |
| 2 = (Ambulatory but unable to work) | 17 |
| 3 = (Limited self care) | 1 |
| 4 = (Completely Disabled) | 0 |
| Renal function at baseline(Participants) | Lenalidomide |
|---|---|
| Normal (CrCl > = 60 mL/min) | 99 |
| Moderate Renal Insufficiency (CrCl ≥ 30 and < 60mL | 28 |
| Severe Renal Insufficiency (CrCl < 30 mL/min) | 1 |
| Missing | 6 |
| Duration of Mantle Cell Lymphoma(years) | Lenalidomide |
|---|---|
| <3 years | 52 |
| ≥ 3 years | 82 |
| MCL (Ann Arbor) Stage at Diagnosis(Participants) | Lenalidomide |
|---|---|
| I | 2 |
| II | 5 |
| III | 19 |
| IV | 105 |
| Missing | 3 |
4 further baseline measures are reported on the registry.
Ran from Dec 2008 to primary completion in Apr 2016, 87 months.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 87 months is above that.
Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide